Human Peripheral Blood Leukapheresis Pack, Fresh

Primary human cells, fresh

More Views

From: 1,739 USD

Options

* Required Fields

Catalog # (Select a product)
Primary human cells, fresh
From: 1,739 USD

Overview

Leukapheresis Packs (also known as leukopaks), are an enriched leukapheresis product consisting of a large number of single-donor mononuclear cells (MNCs) collected from normal peripheral blood. Leukapheresis is performed on normal donors using Institutional Review Board (IRB)-approved consent forms and protocols. Approximately two to three blood volumes are processed using the Spectra Optia® Apheresis System (unless otherwise requested) to produce a full-sized Leukapheresis Pack. Acid citrate dextrose, solution A (ACDA) is the anticoagulant. High-resolution HLA typing for Class I and Class II alleles and CMV status are available upon request.

Certain products are only available in select territories. Please contact your local Sales representative or Product & Scientific Support at techsupport@stemcell.com for further information and to inquire about donor selection or information including BMI category, smoking status, ethnicity, etc.
Subtype:
Fresh
Cell Type:
Leukapheresis Packs
Species:
Human
Cell and Tissue Source:
Peripheral Blood
Donor Status:
Normal

Scientific Resources

Product Documentation

Document Type
Product Name
Catalog #
Lot #
Language

Educational Materials

(3)

Data and Publications

Publications

(1)
Biotechnology and bioengineering 2017

Integrated gut/liver microphysiological systems elucidates inflammatory inter-tissue crosstalk.

Chen WLK et al.

Abstract

A capability for analyzing complex cellular communication among tissues is important in drug discovery and development, and in vitro technologies for doing so are required for human applications. A prominent instance is communication between the gut and the liver, whereby perturbations of one tissue can influence behavior of the other. Here, we present a study on human gut-liver tissue interactions under normal and inflammatory contexts, via an integrative multi-organ platform comprising human liver (hepatocytes and Kupffer cells), and intestinal (enterocytes, goblet cells, and dendritic cells) models. Our results demonstrated long-term (>2 weeks) maintenance of intestinal (e.g., barrier integrity) and hepatic (e.g., albumin) functions in baseline interaction. Gene expression data comparing liver in interaction with gut, versus isolation, revealed modulation of bile acid metabolism. Intestinal FGF19 secretion and associated inhibition of hepatic CYP7A1 expression provided evidence of physiologically relevant gut-liver crosstalk. Moreover, significant non-linear modulation of cytokine responses was observed under inflammatory gut-liver interaction; for example, production of CXCR3 ligands (CXCL9,10,11) was synergistically enhanced. RNA-seq analysis revealed significant upregulation of IFNα/β/γ signaling during inflammatory gut-liver crosstalk, with these pathways implicated in the synergistic CXCR3 chemokine production. Exacerbated inflammatory response in gut-liver interaction also negatively affected tissue-specific functions (e.g., liver metabolism). These findings illustrate how an integrated multi-tissue platform can generate insights useful for understanding complex pathophysiological processes such as inflammatory organ crosstalk. Biotechnol. Bioeng. 2017;114: 2648-2659. textcopyright 2017 Wiley Periodicals, Inc.
STEMCELL TECHNOLOGIES INC.’S QUALITY MANAGEMENT SYSTEM IS CERTIFIED TO ISO 13485. PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED.